Federico Pulido

Universidad Complutense de Madrid — Spain

Medicine · Health Sciences

46h-index7.6kcitations305works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS drug development and treatment(156), HIV Research and Treatment(123), HIV/AIDS Research and Interventions(109), HIV-related health complications and treatments(61), Pneumocystis jirovecii pneumonia detection and treatment(49)

Publications290 total

Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases·2025Open Access
Antiretroviral treatment in people living with HIV with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: A real‐world cohort analysis
HIV Medicine·2025
Impact of antiretroviral regimens containing integrase inhibitors on achieving viral suppression at ultra-low levels compared to other antiretroviral therapy strategies
AIDS·2025
Dolutegravir (DTG) + Lamivudine (3 TC) in Antiretroviral-Naive Adults With HIV With and Without Genotypic Resistance Testing Results: 96-Week Effectiveness and Tolerability of REDOLA Study
JAIDS Journal of Acquired Immune Deficiency Syndromes·2025· 1 cited
Impact of the initial administration of an antiretroviral drug with latency reversal properties on the HIV reservoir size
Scientific Reports·2025· 3 citedOpen Access
Cost-effectiveness of cabotegravir versus tenofovir alafenamide plus emtricitabine versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual and other men that have sex with men
Enfermedades infecciosas y microbiologia clinica (English ed )·2025
Dolutegravir/Lamivudine for Maintenance of Virological Suppression in Persons With Historical Suspected or Confirmed Resistance to Lamivudine: Week 48 Results of a Single-Arm, Open-Label, Multicenter, Phase IIa Clinical Trial
Clinical Infectious Diseases·2025· 4 cited
Cost-effectiveness of cabotegravir versus tenofovir alafenamide plus emtricitabine versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual and other men that have sex with men
Enfermedades Infecciosas y Microbiología Clínica·2025· 2 cited
Open repair of a type IV thoracoabdominal aortic aneurysm using a novel modified technique: branch-first with axillary perfusion limb; first case in Colombia
Angiología·2025Open Access
Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks
Journal of Antimicrobial Chemotherapy·2024· 2 citedOpen Access
Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians
The Lancet HIV·2024· 14 cited
Dolutegravir/Lamivudine for Maintenance of Virological Suppression in Persons with Resistance to Lamivudine: Week 48 Results of a Single-Arm, Open-Label, Multicentre, Phase IIa Clinical Trial
SSRN Electronic Journal·2024Open Access
Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events
EBioMedicine·2023· 32 citedOpen Access
Deep Sequencing on Proviral DNA: More Questions than Answers
JAIDS Journal of Acquired Immune Deficiency Syndromes·2023
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice
Journal of Antimicrobial Chemotherapy·2023· 26 citedOpen Access
Healthcare outcomes in patients with HIV infection at a tertiary hospital during the COVID-19 pandemic
Enfermedades infecciosas y microbiologia clinica (English ed )·2023· 2 citedOpen Access
Corrigendum to “Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)”
EBioMedicine·2023· 1 citedOpen Access
Comparison of the accuracy of the 7-item HADS Depression subscale and 14-item total HADS for screening for major depression: A systematic review and individual participant data meta-analysis.
Psychological Assessment·2023· 10 citedOpen Access
48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort
PLoS ONE·2022· 18 citedOpen Access
Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance
Open Forum Infectious Diseases·2022· 13 citedOpen Access
page 1 of 15Next →

Frequent Co-authors

Rafael Rubio(22), José Ramón Arribas(19), Juan Berenguer(15), Juan González‐García(14), José Antonio Iribarren(11), Marisa Montes(9), Rafaël Delgado(8), Joaquín Portilla(8), Félix Gutiérrez(8), Santiago Moreno(8), Antonio Rivero(8), Daniel Podzamczer(7), María Jesús Téllez(7), José Sanz(7), Ignacio de los Santos(7), Alberto Arranz(7), Pilar Miralles(6), Fernando Dronda(6), Peré Domingo(6), Marta Montero(6)